1-8 of 8
November McGarvey
Close
Save search
Sort by
Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Free
Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 7257.
https://doi.org/10.1182/blood-2023-178771
Published: 2023
Journal Articles

Cytokine Release Syndrome and Neurological Event Management Resource Use and Costs Among Patients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Lisocabtagene Maraleucel Treatment in TRANSFORM and PILOT

Free
November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 3717.
https://doi.org/10.1182/blood-2023-177989
Published: 2023
Journal Articles

Health Care Resource Utilization (HCRU) and Cost of Management of Cytokine Release Syndrome (CRS) and Neurological Events (NEs) in Patients with R/R CLL/SLL Receiving Lisocabtagene Maraleucel (liso-cel) Treatment in the TRANSCEND CLL 004 Study

Free
Farrukh T. Awan, November McGarvey, Abraham Lee, Ken Imanak, Simran K. Tiwana, Sean Garrison, Masoom Priyadarshini
Journal: Blood
Blood (2023) 142 (Supplement 1): 7252.
https://doi.org/10.1182/blood-2023-178048
Published: 2023
Journal Articles

Healthcare Resource Utilization and Economic Burden of Cytokine Release Syndrome and Neurotoxicity in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Receiving Idecabtagene Vicleucel in Earlier-Line Settings in the KarMMa-3 Clinical Trial

Free
Sikander Ailawadhi, November McGarvey, Ken Imanak, Sana Mirza, Pallavi Patwardhan
Journal: Blood
Blood (2023) 142 (Supplement 1): 3712.
https://doi.org/10.1182/blood-2023-173938
Published: 2023
Journal Articles

Estimation of Postinfusion Resource Use and Total Costs of Care for Patients with R/R Follicular Lymphoma (FL) Receiving Lisocabtagene Maraleucel (liso-cel) in the TRANSCEND FL Study

Free
Ashley C. Saunders, Tavneet Singh, Abraham Lee, Thalia Farazi, Omotayo Fasan, Sana Mirza, November McGarvey
Journal: Blood
Blood (2023) 142 (Supplement 1): 5084.
https://doi.org/10.1182/blood-2023-178761
Published: 2023
Journal Articles

Postinfusion Monitoring Health Care Resource Utilization and Costs By Site of Care Among Inpatients and Outpatients with Relapsed or Refractory Large B-Cell Lymphoma Who Received Second-Line Treatment with Lisocabtagene Maraleucel in the TRANSFORM and PILOT Clinical Trials

Free
November McGarvey, Matthew Gitlin, Abraham Lee, Scott J. Keating, Victoria Barghout, Simran K. Tiwana
Journal: Blood
Blood (2023) 142 (Supplement 1): 2340.
https://doi.org/10.1182/blood-2023-178017
Published: 2023
Journal Articles

Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

Free
November McGarvey, Thomas Carattini, Brian Ung, Timothy B. Campbell, Ken Imanak, Pallavi Patwardhan
Journal: Blood
Blood (2022) 140 (Supplement 1): 10947–10948.
https://doi.org/10.1182/blood-2022-158190
Published: 2022
Journal Articles

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

Free
M. Lia Palomba, MD, Monika P. Jun, MPH, Jacob Garcia, MD, James Lymp, PhD, November McGarvey, Matthew Gitlin, Corey Pelletier, Andy Nguyen
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-141415
Published: 2020